These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29588695)

  • 1. Patient-tailored Drug-eluting Stent Choice - A Solution for Patients with Diabetes: Proceedings of Two Satellite Symposia Held at EuroPCR in May 2015 in Paris.
    Mountfort K; Mehran R; Colombo A; Stella P; Romaguera R; Sardella G
    Interv Cardiol; 2015 Sep; 10(3):158-161. PubMed ID: 29588695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cre8™ Unique Technology in Challenging Daily Practice: Proceedings of a satellite symposium held at EuroPCR on 20th - 23rd May 2014 in Paris.
    Mountfort K; Antoniucci D; Mehran R; DeLuca G; Nef H; Vrolix M; Khashaba A
    Interv Cardiol; 2014 Aug; 9(3):180-183. PubMed ID: 29588799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorbable Polymer Technology - Viable Solutions for Unmet Needs in PCI: Proceedings of two satellite symposia held at EuroPCR, Paris in May 2015.
    Mountfort K; Khashaba A; Garbo R; Tigen K; Moellmann H; Morice MC
    Interv Cardiol; 2015 Sep; 10(3):162-166. PubMed ID: 29588696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meeting the Unmet - The Cre8 Polymer-free Drug-eluting Stents Technology: Proceedings of a satellite symposium held at EuroPCR on May 20th - 23rd 2014 in Paris.
    Mountfort K; Carrié D; Valgimigli M; Sardella G; Banai S; Romaguera R; Stella P
    Interv Cardiol; 2014 Aug; 9(3):184-189. PubMed ID: 29588800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of the Cre8 Stent in Patients With Diabetes Mellitus.
    Carrié D
    Interv Cardiol; 2016 May; 11(1):47-50. PubMed ID: 29588705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal duration of dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes: The SECURITY (Second-Generation Drug-Eluting Stent Implantation Followed By Six- Versus Twelve-Month Dual Antiplatelet Therapy)-diabetes substudy.
    Tarantini G; Nai Fovino L; Tellaroli P; Chieffo A; Barioli A; Menozzi A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Dominguez JF; Steffanon L; Presbitero P; Pucci E; Fraccaro C; Mauri J; Giustino G; Sardella G; Colombo A
    Int J Cardiol; 2016 Mar; 207():168-76. PubMed ID: 26803236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stent thrombosis with drug-eluting stents: is the paradigm shifting?
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Genereux P; Branzi A; Stone GW
    J Am Coll Cardiol; 2013 Nov; 62(21):1915-1921. PubMed ID: 24036025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCI in Patients with Diabetes: Role of the Cre8 Drug-eluting Stent.
    Byrne RA; Eeckhout E; Sardella G; Stella P; Verheye S
    Interv Cardiol; 2017 May; 12(1):13-17. PubMed ID: 29588724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of diabetes mellitus on 2-year clinical outcomes following PCI with second-generation drug-eluting stents; Landmark analysis findings from patient registry: Pooled analysis of the Korean multicenter drug-eluting stent registry.
    Lee CH; Choi SW; Jun SW; Hwang J; Kim IC; Cho YK; Park HS; Yoon HJ; Kim H; Nam CW; Han S; Kim KB; Hur SH
    PLoS One; 2020; 15(6):e0234362. PubMed ID: 32520973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal revascularization in diabetes after the FREEDOM trial: were the controversies finally settled?
    Tenenbaum A; Fisman EZ
    Cardiol J; 2013; 20(4):331-6. PubMed ID: 23913450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year clinical outcomes between biodegradable-polymer-coated biolimus-eluting stent and durable-polymer-coated drug-eluting stents in STEMI patients with multivessel coronary artery disease undergoing culprit-only or multivessel PCI.
    Kim YH; Her AY; Jeong MH; Kim BK; Lee SY; Hong SJ; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Atherosclerosis; 2019 May; 284():102-109. PubMed ID: 30877937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents.
    Baber U; Stefanini GG; Giustino G; Stone GW; Leon MB; Sartori S; Aquino M; Steg PG; Windecker S; Wijns W; Serruys PW; Valgimigli M; Morice MC; Camenzind E; Weisz G; Smits PC; Kandzari DE; von Birgelen C; Dangas GD; Galatius S; Jeger RV; Kimura T; Mikhail GW; Itchhaporia D; Mehta L; Ortega R; Kim HS; Kastrati A; Chieffo A; Mehran R
    Circ Cardiovasc Interv; 2019 Jul; 12(7):e007734. PubMed ID: 31288561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymer-free drug-eluting stent in unselected patient population: a single center experience.
    Konigstein M; Banai S; Herz I; Bazan S; Revivo M; Halkin A; Keren G; Finkelstein A; Arbel Y
    Cardiovasc Revasc Med; 2014; 15(6-7):350-3. PubMed ID: 25262477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of Dual Antiplatelet Therapy and Late Stent Thrombosis Following Percutaneous Coronary Intervention with Second-Generation Drug-Eluting Stents: A Simple Meta-Analysis of Randomized Controlled Trials.
    Lin BY; Li P; Wu P; Jiang RN; Bundhun PK; Ahmed MA
    Adv Ther; 2019 Nov; 36(11):3166-3173. PubMed ID: 31535329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and Late Stent Thrombosis in Patients with Versus Without Diabetes Mellitus Following Percutaneous Coronary Intervention with Drug-Eluting Stents: A Systematic Review and Meta-Analysis.
    Yuan J; Xu GM
    Am J Cardiovasc Drugs; 2018 Dec; 18(6):483-492. PubMed ID: 30132141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of the Orsiro Hybrid drug-eluting stent in high-risk subgroups.
    Iglesias JF; Muller O; Zuffi A; Eeckhout E
    Minerva Cardioangiol; 2016 Feb; 64(1):55-73. PubMed ID: 26542119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
    Harada Y; Colleran R; Kufner S; Giacoppo D; Rheude T; Michel J; Cassese S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
    Cardiovasc Diabetol; 2016 Sep; 15(1):124. PubMed ID: 27586678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Very late stent thrombosis with second generation drug eluting stents compared to bare metal stents: Network meta-analysis of randomized primary percutaneous coronary intervention trials.
    Philip F; Stewart S; Southard JA
    Catheter Cardiovasc Interv; 2016 Jul; 88(1):38-48. PubMed ID: 26916633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
    JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.